TARRYTOWN, N.Y. - A COVID-19 antibody cocktail developed by U.S. drugmaker Regeneron offered strong protection against symptomatic infection when given to people living with someone else infected with ...

Nov 17 (Reuters) - Roche Holding AG (ROG.S), opens new tab has completed early tests of its ability to produce large quantities of Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab COVID-19 ...

Oct 30 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody ...

Regeneron’s COVID-19 antibody cocktail, casirivimab and imdevimab, reduced the risk of death among hospitalized patients in a phase 3 trial, the drugmaker said June 16. The trial found that adding ...

LONDON - Initial results from a large study in the U.K. found that an antibody drug reduced death in hospitalized COVID-19 patients who faced the highest risk from the virus. The study was led by the ...

After news broke last weekend that President Donald Trump tested positive for COVID-19, Regeneron CEO Leonard Schleifer ’73 was once again thrust into the spotlight, running the biotech company ...

About 30,000 doses of an experimental coronavirus treatment are shipping out Tuesday. It's Regeneron's antibody cocktail that got an emergency use authorization (EUA) from the Food and Drug ...

The pause affects Sotrovimab from GlaxoSmithKline. The federal government is sharply pulling back on one of the monoclonal antibody treatments authorized for COVID-19, pausing its use across eight ...

HHS said Feb. 4 it is working with Regeneron Pharmaceuticals to develop a treatment for the coronavirus. The agency said it will work to develop multiple monoclonal antibodies, which help block a ...

The race is on for new treatments that stand up to omicron's explosive spread. With omicron's explosive spread threatening to outpace current COVID-19 treatments, the race is on to find new options ...

It’s far from business as usual at the Indianapolis headquarters of Eli Lilly, with only a sixth of the pharma company’s employees working on-site to develop potential Covid-19 treatments. WSJ’s Peter ...